| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 60 | 2024 | 1248 | 12.120 |
Why?
|
| 3-Iodobenzylguanidine | 32 | 2023 | 114 | 7.050 |
Why?
|
| Bone Neoplasms | 46 | 2024 | 2525 | 6.560 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 38 | 2024 | 11709 | 2.200 |
Why?
|
| Gene Amplification | 8 | 2022 | 1086 | 2.150 |
Why?
|
| Neoplasms | 49 | 2024 | 21990 | 2.000 |
Why?
|
| Neoplasm Recurrence, Local | 35 | 2024 | 9245 | 1.980 |
Why?
|
| Osteosarcoma | 13 | 2024 | 896 | 1.880 |
Why?
|
| Antineoplastic Agents | 37 | 2024 | 13603 | 1.850 |
Why?
|
| Radiopharmaceuticals | 19 | 2023 | 2634 | 1.740 |
Why?
|
| Neoplasms, Second Primary | 10 | 2022 | 1051 | 1.670 |
Why?
|
| Child | 156 | 2024 | 79787 | 1.580 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 4 | 2023 | 43 | 1.570 |
Why?
|
| Adrenal Gland Neoplasms | 7 | 2022 | 732 | 1.570 |
Why?
|
| Iodine Radioisotopes | 12 | 2022 | 1032 | 1.470 |
Why?
|
| Radiation-Sensitizing Agents | 6 | 2022 | 346 | 1.410 |
Why?
|
| Child, Preschool | 97 | 2024 | 42044 | 1.410 |
Why?
|
| Vincristine | 12 | 2023 | 1036 | 1.390 |
Why?
|
| Bone Marrow Neoplasms | 2 | 2020 | 101 | 1.310 |
Why?
|
| Medical Oncology | 16 | 2023 | 2308 | 1.280 |
Why?
|
| Infant | 71 | 2024 | 36043 | 1.130 |
Why?
|
| Salvage Therapy | 7 | 2021 | 1264 | 1.110 |
Why?
|
| Adolescent | 113 | 2024 | 87832 | 1.080 |
Why?
|
| Pyrimidines | 9 | 2022 | 3005 | 1.060 |
Why?
|
| Sarcoma | 10 | 2023 | 1784 | 1.060 |
Why?
|
| Receptor, trkA | 4 | 2020 | 159 | 0.980 |
Why?
|
| Clinical Trials, Phase I as Topic | 4 | 2023 | 326 | 0.970 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 4 | 2023 | 66 | 0.950 |
Why?
|
| Soft Tissue Neoplasms | 5 | 2023 | 1152 | 0.910 |
Why?
|
| Prognosis | 42 | 2023 | 29493 | 0.900 |
Why?
|
| Paraganglioma | 2 | 2022 | 142 | 0.880 |
Why?
|
| Drug Resistance, Neoplasm | 11 | 2021 | 5254 | 0.870 |
Why?
|
| SEER Program | 13 | 2020 | 1454 | 0.870 |
Why?
|
| Camptothecin | 3 | 2016 | 589 | 0.860 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2021 | 916 | 0.810 |
Why?
|
| Glomus Tumor | 1 | 2022 | 62 | 0.780 |
Why?
|
| Maximum Tolerated Dose | 10 | 2023 | 877 | 0.770 |
Why?
|
| Humans | 209 | 2024 | 757650 | 0.760 |
Why?
|
| Clinical Trials as Topic | 12 | 2024 | 7982 | 0.760 |
Why?
|
| Indenes | 1 | 2021 | 58 | 0.740 |
Why?
|
| Vesicular Monoamine Transport Proteins | 2 | 2023 | 32 | 0.740 |
Why?
|
| Pathology, Molecular | 2 | 2021 | 327 | 0.730 |
Why?
|
| Polycythemia | 1 | 2021 | 125 | 0.730 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2020 | 628 | 0.720 |
Why?
|
| Young Adult | 63 | 2024 | 58764 | 0.710 |
Why?
|
| Minors | 1 | 2020 | 58 | 0.700 |
Why?
|
| Calmodulin-Binding Proteins | 2 | 2011 | 232 | 0.680 |
Why?
|
| Gene Fusion | 2 | 2019 | 354 | 0.680 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2020 | 102 | 0.680 |
Why?
|
| Off-Label Use | 2 | 2024 | 185 | 0.670 |
Why?
|
| Age Factors | 16 | 2020 | 18328 | 0.630 |
Why?
|
| Disease-Free Survival | 14 | 2023 | 6808 | 0.620 |
Why?
|
| Radionuclide Imaging | 5 | 2022 | 1976 | 0.610 |
Why?
|
| Oncogene Proteins, Fusion | 10 | 2023 | 1594 | 0.600 |
Why?
|
| Industry | 1 | 2020 | 361 | 0.600 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2022 | 620 | 0.600 |
Why?
|
| Pelvic Neoplasms | 2 | 2022 | 247 | 0.590 |
Why?
|
| Kaplan-Meier Estimate | 14 | 2018 | 6469 | 0.590 |
Why?
|
| Azepines | 2 | 2018 | 329 | 0.590 |
Why?
|
| Ganglioneuroma | 1 | 2017 | 53 | 0.570 |
Why?
|
| Ifosfamide | 7 | 2023 | 232 | 0.570 |
Why?
|
| Male | 109 | 2024 | 358227 | 0.560 |
Why?
|
| Pyrazoles | 5 | 2022 | 1994 | 0.550 |
Why?
|
| Oncogene Proteins | 4 | 2015 | 719 | 0.550 |
Why?
|
| Hydroxamic Acids | 3 | 2015 | 481 | 0.550 |
Why?
|
| Pyrroles | 4 | 2021 | 1127 | 0.550 |
Why?
|
| Thoracic Neoplasms | 2 | 2019 | 265 | 0.540 |
Why?
|
| Benzazepines | 1 | 2018 | 310 | 0.540 |
Why?
|
| Survival Rate | 16 | 2023 | 12685 | 0.540 |
Why?
|
| Etoposide | 7 | 2023 | 634 | 0.540 |
Why?
|
| Research Support as Topic | 2 | 2020 | 697 | 0.540 |
Why?
|
| Female | 109 | 2024 | 389985 | 0.510 |
Why?
|
| Wilms Tumor | 3 | 2015 | 375 | 0.510 |
Why?
|
| Neoplasm Staging | 15 | 2022 | 11083 | 0.510 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2019 | 338 | 0.510 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 1135 | 0.510 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2019 | 547 | 0.500 |
Why?
|
| Molecular Targeted Therapy | 10 | 2022 | 2796 | 0.490 |
Why?
|
| Bone Marrow | 5 | 2020 | 2910 | 0.480 |
Why?
|
| Indoles | 4 | 2021 | 1825 | 0.480 |
Why?
|
| Cyclophosphamide | 6 | 2023 | 2219 | 0.470 |
Why?
|
| Radiotherapy | 3 | 2019 | 1498 | 0.470 |
Why?
|
| Protein Kinase Inhibitors | 11 | 2024 | 5639 | 0.460 |
Why?
|
| Adult | 68 | 2023 | 219747 | 0.460 |
Why?
|
| Infant, Newborn | 23 | 2022 | 26173 | 0.450 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2011 | 940 | 0.440 |
Why?
|
| Dysostoses | 1 | 2012 | 7 | 0.430 |
Why?
|
| Nuclear Proteins | 8 | 2023 | 5786 | 0.430 |
Why?
|
| Doxorubicin | 8 | 2023 | 2211 | 0.420 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 586 | 0.420 |
Why?
|
| Dacarbazine | 1 | 2016 | 559 | 0.420 |
Why?
|
| Gene Dosage | 1 | 2017 | 1218 | 0.420 |
Why?
|
| Annexin A5 | 1 | 2012 | 103 | 0.410 |
Why?
|
| Chromosome Aberrations | 5 | 2022 | 1764 | 0.410 |
Why?
|
| Treatment Outcome | 30 | 2021 | 64242 | 0.400 |
Why?
|
| RNA-Binding Proteins | 2 | 2011 | 1895 | 0.400 |
Why?
|
| Neoplasm Metastasis | 9 | 2019 | 4888 | 0.390 |
Why?
|
| Follow-Up Studies | 23 | 2024 | 39018 | 0.390 |
Why?
|
| Retrospective Studies | 40 | 2024 | 79982 | 0.380 |
Why?
|
| Histones | 3 | 2018 | 2577 | 0.370 |
Why?
|
| Combined Modality Therapy | 14 | 2022 | 8515 | 0.360 |
Why?
|
| Neovascularization, Pathologic | 3 | 2014 | 2638 | 0.360 |
Why?
|
| Carcinoma | 5 | 2022 | 2330 | 0.360 |
Why?
|
| Gastrointestinal Stromal Tumors | 3 | 2021 | 615 | 0.360 |
Why?
|
| RNA-Binding Protein EWS | 3 | 2021 | 210 | 0.340 |
Why?
|
| Topotecan | 2 | 2021 | 132 | 0.330 |
Why?
|
| Cohort Studies | 18 | 2020 | 41198 | 0.330 |
Why?
|
| Sirolimus | 4 | 2017 | 1532 | 0.320 |
Why?
|
| Mortality | 1 | 2020 | 2881 | 0.320 |
Why?
|
| Proportional Hazards Models | 7 | 2017 | 12400 | 0.320 |
Why?
|
| United States Food and Drug Administration | 7 | 2023 | 1658 | 0.320 |
Why?
|
| Introns | 1 | 2011 | 978 | 0.310 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2022 | 5648 | 0.310 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2020 | 1546 | 0.290 |
Why?
|
| United States | 24 | 2024 | 71907 | 0.290 |
Why?
|
| Biomedical Research | 2 | 2020 | 3416 | 0.290 |
Why?
|
| Translocation, Genetic | 3 | 2021 | 1387 | 0.290 |
Why?
|
| Kidney Neoplasms | 6 | 2017 | 4221 | 0.290 |
Why?
|
| Neoplasm Proteins | 2 | 2021 | 3608 | 0.280 |
Why?
|
| Tissue Distribution | 5 | 2021 | 2263 | 0.280 |
Why?
|
| Cytarabine | 1 | 2009 | 697 | 0.280 |
Why?
|
| Glioma | 4 | 2024 | 3417 | 0.280 |
Why?
|
| Loss of Heterozygosity | 3 | 2019 | 659 | 0.280 |
Why?
|
| Databases, Factual | 4 | 2018 | 7926 | 0.270 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 2326 | 0.260 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2008 | 255 | 0.260 |
Why?
|
| Fibrosarcoma | 2 | 2018 | 308 | 0.260 |
Why?
|
| Drug Administration Schedule | 6 | 2020 | 4845 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2022 | 8505 | 0.260 |
Why?
|
| Neoadjuvant Therapy | 5 | 2022 | 2809 | 0.260 |
Why?
|
| Pheochromocytoma | 2 | 2022 | 328 | 0.260 |
Why?
|
| Drug Approval | 4 | 2023 | 808 | 0.260 |
Why?
|
| Drug Dosage Calculations | 3 | 2020 | 117 | 0.250 |
Why?
|
| Lymphocyte Count | 1 | 2007 | 778 | 0.240 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2021 | 951 | 0.230 |
Why?
|
| Gene Frequency | 1 | 2011 | 3612 | 0.230 |
Why?
|
| Ferritins | 2 | 2019 | 597 | 0.230 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2014 | 2047 | 0.230 |
Why?
|
| Time Factors | 12 | 2022 | 39815 | 0.220 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2023 | 10750 | 0.220 |
Why?
|
| Logistic Models | 4 | 2022 | 13222 | 0.220 |
Why?
|
| Flow Cytometry | 3 | 2011 | 5864 | 0.220 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 6325 | 0.210 |
Why?
|
| Sarcoma, Small Cell | 1 | 2023 | 17 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 5 | 2023 | 9163 | 0.210 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2023 | 42 | 0.210 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2022 | 1622 | 0.210 |
Why?
|
| Radiometry | 4 | 2016 | 813 | 0.210 |
Why?
|
| Radiotherapy Dosage | 5 | 2024 | 2895 | 0.210 |
Why?
|
| Poverty | 2 | 2024 | 2688 | 0.200 |
Why?
|
| Neutropenia | 3 | 2017 | 885 | 0.200 |
Why?
|
| Normetanephrine | 1 | 2021 | 25 | 0.200 |
Why?
|
| Brain Neoplasms | 7 | 2022 | 8981 | 0.200 |
Why?
|
| Leukemia, Lymphoid | 1 | 2002 | 310 | 0.200 |
Why?
|
| Proteins | 3 | 2021 | 6026 | 0.190 |
Why?
|
| Lymph Nodes | 1 | 2013 | 3474 | 0.190 |
Why?
|
| Whole-Body Irradiation | 3 | 2016 | 433 | 0.190 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2022 | 80 | 0.190 |
Why?
|
| Survival Analysis | 7 | 2020 | 10075 | 0.190 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 2021 | 67 | 0.190 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2018 | 772 | 0.190 |
Why?
|
| Genomics | 7 | 2022 | 5788 | 0.190 |
Why?
|
| Chromogranins | 1 | 2021 | 161 | 0.190 |
Why?
|
| Rhabdomyosarcoma | 2 | 2023 | 358 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2019 | 2913 | 0.180 |
Why?
|
| Cell Cycle Proteins | 4 | 2022 | 3443 | 0.180 |
Why?
|
| Chi-Square Distribution | 2 | 2020 | 3415 | 0.180 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2014 | 411 | 0.180 |
Why?
|
| Registries | 2 | 2020 | 8164 | 0.180 |
Why?
|
| Drug Monitoring | 2 | 2018 | 960 | 0.180 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2022 | 2419 | 0.180 |
Why?
|
| Lymphoma | 2 | 2019 | 1900 | 0.180 |
Why?
|
| Alleles | 1 | 2011 | 6894 | 0.170 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 2882 | 0.170 |
Why?
|
| Cell Line, Tumor | 5 | 2022 | 16891 | 0.170 |
Why?
|
| Indole Alkaloids | 1 | 2019 | 23 | 0.170 |
Why?
|
| Diketopiperazines | 1 | 2019 | 24 | 0.170 |
Why?
|
| Drug Industry | 3 | 2021 | 787 | 0.170 |
Why?
|
| DNA Glycosylases | 1 | 2020 | 124 | 0.170 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2022 | 3613 | 0.170 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 3319 | 0.170 |
Why?
|
| Research Subjects | 1 | 2021 | 249 | 0.170 |
Why?
|
| Prenylation | 1 | 2019 | 37 | 0.170 |
Why?
|
| Mutation | 9 | 2020 | 29928 | 0.170 |
Why?
|
| Disease Progression | 8 | 2024 | 13464 | 0.170 |
Why?
|
| Receptor, Notch1 | 1 | 2022 | 494 | 0.160 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2022 | 2004 | 0.160 |
Why?
|
| Government | 1 | 2020 | 161 | 0.160 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2021 | 2506 | 0.160 |
Why?
|
| Standard of Care | 1 | 2023 | 550 | 0.160 |
Why?
|
| Adrenal Glands | 1 | 2021 | 553 | 0.160 |
Why?
|
| Prospective Studies | 11 | 2023 | 54108 | 0.160 |
Why?
|
| Neoplasms, Connective and Soft Tissue | 1 | 2019 | 34 | 0.160 |
Why?
|
| Nomograms | 1 | 2020 | 227 | 0.160 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2024 | 2056 | 0.160 |
Why?
|
| Risk Factors | 12 | 2020 | 73716 | 0.160 |
Why?
|
| Genomic Structural Variation | 1 | 2018 | 63 | 0.160 |
Why?
|
| Calcitonin | 1 | 2019 | 330 | 0.150 |
Why?
|
| Carbazoles | 1 | 2019 | 220 | 0.150 |
Why?
|
| Endothelial Cells | 1 | 2011 | 3533 | 0.150 |
Why?
|
| Ribonuclease III | 1 | 2020 | 279 | 0.150 |
Why?
|
| Germ-Line Mutation | 4 | 2020 | 1840 | 0.150 |
Why?
|
| Lung Neoplasms | 5 | 2023 | 13267 | 0.150 |
Why?
|
| Nephroma, Mesoblastic | 1 | 2017 | 24 | 0.150 |
Why?
|
| Stem Cells | 1 | 2011 | 3521 | 0.150 |
Why?
|
| Legislation, Drug | 1 | 2020 | 214 | 0.150 |
Why?
|
| Academies and Institutes | 1 | 2020 | 318 | 0.150 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2018 | 171 | 0.150 |
Why?
|
| Signal Transduction | 3 | 2024 | 23342 | 0.140 |
Why?
|
| Blood Pressure | 1 | 2013 | 8452 | 0.140 |
Why?
|
| Research Design | 3 | 2023 | 6151 | 0.140 |
Why?
|
| Cancer Care Facilities | 1 | 2020 | 419 | 0.140 |
Why?
|
| Recurrence | 7 | 2022 | 8426 | 0.140 |
Why?
|
| Gene Expression Profiling | 3 | 2019 | 9404 | 0.140 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2020 | 383 | 0.140 |
Why?
|
| Technetium Tc 99m Medronate | 1 | 2017 | 131 | 0.140 |
Why?
|
| Administration, Oral | 4 | 2020 | 3995 | 0.140 |
Why?
|
| Retreatment | 1 | 2018 | 596 | 0.140 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2022 | 1074 | 0.140 |
Why?
|
| Genetic Heterogeneity | 1 | 2020 | 723 | 0.140 |
Why?
|
| Leukemia | 2 | 2016 | 1521 | 0.130 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2020 | 791 | 0.130 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2017 | 675 | 0.130 |
Why?
|
| Survivors | 3 | 2016 | 2370 | 0.130 |
Why?
|
| Leukemia, Myeloid | 1 | 2019 | 695 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 1404 | 0.130 |
Why?
|
| Risk | 3 | 2019 | 9590 | 0.130 |
Why?
|
| Pediatrics | 6 | 2021 | 3586 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 3480 | 0.130 |
Why?
|
| Models, Biological | 3 | 2021 | 9460 | 0.130 |
Why?
|
| Tongue Neoplasms | 1 | 2017 | 183 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 5382 | 0.130 |
Why?
|
| Drug Discovery | 2 | 2020 | 1044 | 0.130 |
Why?
|
| Tablets | 1 | 2016 | 147 | 0.130 |
Why?
|
| Histone Deacetylases | 2 | 2018 | 719 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2024 | 2443 | 0.130 |
Why?
|
| Glucuronosyltransferase | 1 | 2016 | 130 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2023 | 4491 | 0.130 |
Why?
|
| Blood Sedimentation | 1 | 2016 | 234 | 0.120 |
Why?
|
| Syndrome | 1 | 2021 | 3261 | 0.120 |
Why?
|
| Pelvic Bones | 1 | 2017 | 270 | 0.120 |
Why?
|
| Neoplasm, Residual | 1 | 2020 | 1005 | 0.120 |
Why?
|
| Tumor Burden | 4 | 2019 | 1887 | 0.120 |
Why?
|
| Rhabdoid Tumor | 1 | 2017 | 210 | 0.120 |
Why?
|
| Acetylation | 2 | 2015 | 1060 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 610 | 0.120 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 2915 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2019 | 15773 | 0.120 |
Why?
|
| Dose-Response Relationship, Radiation | 4 | 2020 | 882 | 0.120 |
Why?
|
| Transplantation, Autologous | 4 | 2021 | 2113 | 0.120 |
Why?
|
| Antibodies, Bispecific | 1 | 2016 | 191 | 0.110 |
Why?
|
| Pyridazines | 1 | 2015 | 200 | 0.110 |
Why?
|
| Mitosis | 1 | 2019 | 1191 | 0.110 |
Why?
|
| Cytoskeletal Proteins | 1 | 2019 | 1342 | 0.110 |
Why?
|
| Purines | 1 | 2017 | 605 | 0.110 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2016 | 380 | 0.110 |
Why?
|
| Genetic Engineering | 1 | 2019 | 933 | 0.110 |
Why?
|
| Paraffin Embedding | 1 | 2014 | 302 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2017 | 555 | 0.110 |
Why?
|
| Aminopyridines | 1 | 2017 | 564 | 0.110 |
Why?
|
| Cisplatin | 3 | 2022 | 1647 | 0.110 |
Why?
|
| Incidence | 6 | 2020 | 21217 | 0.110 |
Why?
|
| International Cooperation | 2 | 2021 | 1429 | 0.100 |
Why?
|
| Nifedipine | 1 | 2013 | 221 | 0.100 |
Why?
|
| Killer Cells, Natural | 1 | 2002 | 2201 | 0.100 |
Why?
|
| Growth Plate | 1 | 2014 | 274 | 0.100 |
Why?
|
| Immunologic Factors | 1 | 2022 | 1584 | 0.100 |
Why?
|
| Biological Products | 1 | 2022 | 905 | 0.100 |
Why?
|
| Serine Endopeptidases | 1 | 2017 | 1020 | 0.100 |
Why?
|
| Middle Aged | 19 | 2023 | 219219 | 0.100 |
Why?
|
| Models, Animal | 1 | 2018 | 2112 | 0.100 |
Why?
|
| Powders | 1 | 2011 | 79 | 0.100 |
Why?
|
| Extremities | 1 | 2017 | 865 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 2014 | 12047 | 0.100 |
Why?
|
| Pyrrolidinones | 1 | 2012 | 116 | 0.100 |
Why?
|
| Genome | 1 | 2020 | 1739 | 0.100 |
Why?
|
| Aged, 80 and over | 8 | 2023 | 58559 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 10135 | 0.090 |
Why?
|
| Dexmedetomidine | 1 | 2015 | 316 | 0.090 |
Why?
|
| Age Distribution | 1 | 2017 | 2875 | 0.090 |
Why?
|
| Piperidines | 1 | 2019 | 1639 | 0.090 |
Why?
|
| Radiosurgery | 1 | 2020 | 1341 | 0.090 |
Why?
|
| Melanoma | 2 | 2019 | 5690 | 0.090 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 2717 | 0.090 |
Why?
|
| Telangiectasis | 1 | 2010 | 77 | 0.090 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2012 | 259 | 0.090 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2011 | 136 | 0.090 |
Why?
|
| Forecasting | 1 | 2019 | 2919 | 0.090 |
Why?
|
| Antigens, CD | 2 | 2011 | 3997 | 0.080 |
Why?
|
| Risk Assessment | 4 | 2020 | 23819 | 0.080 |
Why?
|
| NF-kappa B | 1 | 2018 | 2472 | 0.080 |
Why?
|
| Proteinuria | 1 | 2012 | 594 | 0.080 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2010 | 117 | 0.080 |
Why?
|
| Aged | 13 | 2023 | 167889 | 0.080 |
Why?
|
| Dactinomycin | 1 | 2009 | 304 | 0.080 |
Why?
|
| Biopsy | 1 | 2020 | 6758 | 0.080 |
Why?
|
| Vasodilator Agents | 1 | 2013 | 973 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2023 | 9265 | 0.080 |
Why?
|
| Gene Expression | 2 | 2018 | 7584 | 0.080 |
Why?
|
| DNA Damage | 1 | 2018 | 2439 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2012 | 570 | 0.080 |
Why?
|
| Stem Cell Transplantation | 2 | 2016 | 1598 | 0.080 |
Why?
|
| Lipoma | 1 | 2010 | 292 | 0.080 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2009 | 125 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2021 | 36271 | 0.070 |
Why?
|
| Statistics, Nonparametric | 3 | 2020 | 2847 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2010 | 367 | 0.070 |
Why?
|
| Hypnotics and Sedatives | 1 | 2015 | 1176 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2020 | 8551 | 0.070 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 3754 | 0.070 |
Why?
|
| Liposarcoma | 1 | 2010 | 283 | 0.070 |
Why?
|
| Boston | 1 | 2020 | 9297 | 0.070 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 2189 | 0.070 |
Why?
|
| Linear Models | 1 | 2017 | 5857 | 0.070 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2014 | 1014 | 0.070 |
Why?
|
| Escherichia coli | 1 | 2019 | 4215 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2022 | 20499 | 0.070 |
Why?
|
| Quinolines | 1 | 2012 | 758 | 0.070 |
Why?
|
| Busulfan | 2 | 2021 | 258 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2022 | 4641 | 0.070 |
Why?
|
| Boronic Acids | 1 | 2010 | 914 | 0.070 |
Why?
|
| Immunohistochemistry | 3 | 2015 | 11065 | 0.070 |
Why?
|
| Drug Utilization | 1 | 2012 | 1187 | 0.060 |
Why?
|
| Melphalan | 2 | 2021 | 420 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2020 | 5068 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 25931 | 0.060 |
Why?
|
| Upper Extremity | 1 | 2010 | 661 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 3510 | 0.060 |
Why?
|
| Carcinoma, Small Cell | 1 | 2007 | 420 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2017 | 3599 | 0.060 |
Why?
|
| Anti-Infective Agents | 1 | 2012 | 981 | 0.060 |
Why?
|
| Acute Disease | 2 | 2013 | 7226 | 0.060 |
Why?
|
| Genotype | 2 | 2016 | 12951 | 0.060 |
Why?
|
| Pyrazines | 1 | 2010 | 1198 | 0.060 |
Why?
|
| Asparaginase | 2 | 2020 | 240 | 0.060 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2007 | 629 | 0.060 |
Why?
|
| Receptors, Progesterone | 1 | 2008 | 1129 | 0.060 |
Why?
|
| Positron-Emission Tomography | 2 | 2022 | 6457 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 1 | 2010 | 1600 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2020 | 1335 | 0.050 |
Why?
|
| Mice, Nude | 3 | 2018 | 3602 | 0.050 |
Why?
|
| Consensus | 2 | 2024 | 3098 | 0.050 |
Why?
|
| Cyclin B | 1 | 2023 | 104 | 0.050 |
Why?
|
| Hospitals, Pediatric | 1 | 2012 | 1853 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2011 | 22024 | 0.050 |
Why?
|
| Phenotype | 2 | 2020 | 16533 | 0.050 |
Why?
|
| Plasma Cell Granuloma, Pulmonary | 1 | 2021 | 12 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 4021 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 2743 | 0.050 |
Why?
|
| Hearing Loss | 1 | 2009 | 781 | 0.050 |
Why?
|
| Animals | 8 | 2020 | 167777 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2016 | 2212 | 0.050 |
Why?
|
| Sacrum | 1 | 2022 | 276 | 0.050 |
Why?
|
| European Union | 1 | 2021 | 157 | 0.050 |
Why?
|
| Clinical Protocols | 2 | 2016 | 1436 | 0.040 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2020 | 33 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2014 | 5243 | 0.040 |
Why?
|
| Nucleotides | 1 | 2023 | 450 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2021 | 17767 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2008 | 2208 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2011 | 2559 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2017 | 7841 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 2 | 2018 | 2001 | 0.040 |
Why?
|
| Tanzania | 2 | 2015 | 1383 | 0.040 |
Why?
|
| Mitoxantrone | 1 | 2020 | 148 | 0.040 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2020 | 114 | 0.040 |
Why?
|
| Drug and Narcotic Control | 1 | 2020 | 145 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 7799 | 0.040 |
Why?
|
| Repressor Proteins | 2 | 2023 | 2976 | 0.040 |
Why?
|
| Therapies, Investigational | 1 | 2020 | 111 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 15209 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2012 | 4937 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 3575 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 886 | 0.040 |
Why?
|
| Dexamethasone | 2 | 2020 | 1927 | 0.040 |
Why?
|
| Radiation Dosage | 2 | 2020 | 1957 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2010 | 1826 | 0.040 |
Why?
|
| Heart | 1 | 2011 | 4382 | 0.040 |
Why?
|
| Radiography | 1 | 2009 | 6957 | 0.040 |
Why?
|
| Arabinonucleosides | 1 | 2017 | 34 | 0.040 |
Why?
|
| Adenine Nucleotides | 1 | 2017 | 111 | 0.040 |
Why?
|
| Drug Labeling | 1 | 2020 | 248 | 0.040 |
Why?
|
| Annual Reports as Topic | 1 | 2017 | 36 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 11893 | 0.040 |
Why?
|
| Receptor, trkB | 1 | 2018 | 125 | 0.040 |
Why?
|
| Oncogenes | 1 | 2022 | 1222 | 0.030 |
Why?
|
| Isotretinoin | 1 | 2018 | 132 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2017 | 311 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2017 | 347 | 0.030 |
Why?
|
| Fatal Outcome | 2 | 2012 | 1828 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2004 | 1173 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2021 | 618 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2017 | 362 | 0.030 |
Why?
|
| Germany | 1 | 2018 | 865 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2020 | 799 | 0.030 |
Why?
|
| Benzothiazoles | 1 | 2016 | 246 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2020 | 2922 | 0.030 |
Why?
|
| Morpholines | 1 | 2018 | 580 | 0.030 |
Why?
|
| Stomatitis | 1 | 2016 | 271 | 0.030 |
Why?
|
| Genetic Testing | 2 | 2017 | 3529 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 1188 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 1788 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 1999 | 989 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2011 | 5031 | 0.030 |
Why?
|
| Europe | 1 | 2020 | 3415 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2018 | 1955 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2020 | 1184 | 0.030 |
Why?
|
| Hypertension | 1 | 2013 | 8502 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2016 | 1568 | 0.030 |
Why?
|
| Phenylurea Compounds | 1 | 2016 | 527 | 0.030 |
Why?
|
| Metanephrine | 1 | 2012 | 25 | 0.030 |
Why?
|
| Compassionate Use Trials | 1 | 2012 | 50 | 0.030 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2012 | 43 | 0.030 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2016 | 495 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2021 | 2145 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 4567 | 0.020 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2012 | 72 | 0.020 |
Why?
|
| Minnesota | 1 | 2012 | 338 | 0.020 |
Why?
|
| Base Sequence | 1 | 2022 | 12437 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2011 | 115 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2012 | 273 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2017 | 2636 | 0.020 |
Why?
|
| Conscious Sedation | 1 | 2015 | 529 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2020 | 6336 | 0.020 |
Why?
|
| Cephalosporins | 1 | 2012 | 204 | 0.020 |
Why?
|
| California | 1 | 2015 | 1418 | 0.020 |
Why?
|
| Drug Utilization Review | 1 | 2012 | 248 | 0.020 |
Why?
|
| Protein Kinases | 1 | 2018 | 1610 | 0.020 |
Why?
|
| Epigenomics | 1 | 2016 | 936 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2011 | 317 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 2012 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2015 | 1256 | 0.020 |
Why?
|
| Software | 2 | 2015 | 4416 | 0.020 |
Why?
|
| Inappropriate Prescribing | 1 | 2012 | 208 | 0.020 |
Why?
|
| Age of Onset | 1 | 2016 | 3296 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2011 | 344 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2014 | 1702 | 0.020 |
Why?
|
| Methotrexate | 1 | 2016 | 1718 | 0.020 |
Why?
|
| DNA Repair | 1 | 2018 | 2038 | 0.020 |
Why?
|
| Vancomycin | 1 | 2012 | 503 | 0.020 |
Why?
|
| Luminescent Proteins | 1 | 2011 | 835 | 0.020 |
Why?
|
| Mice | 4 | 2018 | 81107 | 0.020 |
Why?
|
| Health Policy | 1 | 2020 | 2675 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 4710 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 3705 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2010 | 754 | 0.020 |
Why?
|
| Pregnancy | 1 | 2008 | 29720 | 0.020 |
Why?
|
| Prevalence | 1 | 2023 | 15641 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 12950 | 0.020 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2016 | 1392 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2020 | 6198 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 1228 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2012 | 1296 | 0.020 |
Why?
|
| Family Health | 1 | 2010 | 1256 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2007 | 695 | 0.020 |
Why?
|
| Prescription Drugs | 1 | 2012 | 626 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2017 | 3887 | 0.010 |
Why?
|
| Hematologic Neoplasms | 1 | 2016 | 1890 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2008 | 1082 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2021 | 5348 | 0.010 |
Why?
|
| Contrast Media | 1 | 2017 | 5297 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2011 | 1611 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 6128 | 0.010 |
Why?
|
| Developing Countries | 1 | 2015 | 2865 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 2378 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 4047 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2022 | 12092 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 3167 | 0.010 |
Why?
|
| Parents | 1 | 2016 | 3548 | 0.010 |
Why?
|
| Pedigree | 1 | 2010 | 4578 | 0.010 |
Why?
|
| Inflammation | 1 | 2021 | 10718 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2011 | 4258 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2016 | 12761 | 0.010 |
Why?
|
| Cell Survival | 1 | 2011 | 5782 | 0.010 |
Why?
|
| Comorbidity | 1 | 2014 | 10478 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2012 | 3153 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2011 | 10416 | 0.010 |
Why?
|
| Apoptosis | 1 | 2011 | 9469 | 0.010 |
Why?
|
| Quality of Life | 1 | 2012 | 13265 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 20999 | 0.010 |
Why?
|